{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T23:10:36Z","timestamp":1790032236253,"version":"4.0.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T00:00:00Z","timestamp":1787356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":31,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-77068-0","type":"journal-article","created":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T04:55:30Z","timestamp":1787374530000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Glucagon-like Peptide-1 Receptor Agonists and Risk of Tuberculosis in Type 2 Diabetes"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4364-8248","authenticated-orcid":false,"given":"Kuang-Ming","family":"Liao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3290-1909","authenticated-orcid":false,"given":"Jheng-Yan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6334-2388","authenticated-orcid":false,"given":"Chih-Cheng","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,22]]},"reference":[{"key":"77068_CR1","unstructured":"Lee, H., Kim, J., Kim, J. & Park, Y.-J. Review of the global burden of tuberculosis in 2023: insights from the WHO Global Tuberculosis Report 2024 (2025)."},{"key":"77068_CR2","unstructured":"World Health Organization. https:\/\/www.who.int\/news\/item\/29-10-2024-tuberculosis-resurges-as-top-infectious-disease-killer Accessed on July 13, 2025."},{"key":"77068_CR3","unstructured":"World Health Organization. https:\/\/www.who.int\/teams\/global-tuberculosis-programme\/tb-reports\/global-tuberculosis-report-2024 Accessed on July 13, 2025."},{"key":"77068_CR4","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/S1473-3099(09)70282-8","volume":"9","author":"KE Dooley","year":"2009","unstructured":"Dooley, K. E. & Chaisson, R. E. Tuberculosis and diabetes mellitus: convergence of two epidemics. Lancet Infect. Dis. 9, 737\u2013746 (2009).","journal-title":"Lancet Infect. Dis."},{"key":"77068_CR5","doi-asserted-by":"publisher","first-page":"e152","DOI":"10.1371\/journal.pmed.0050152","volume":"5","author":"CY Jeon","year":"2008","unstructured":"Jeon, C. Y. & Murray, M. B. Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLoS Med 5, e152 (2008).","journal-title":"PLoS Med"},{"key":"77068_CR6","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1186\/s12933-024-02500-y","volume":"23","author":"K Sawami","year":"2024","unstructured":"Sawami, K., Tanaka, A. & Node, K. Updated evidence on cardiovascular and renal effects of GLP-1 receptor agonists and combination therapy with SGLT2 inhibitors and finerenone: a narrative review and perspectives. Cardiovasc. Diabetol. 23, 410 (2024).","journal-title":"Cardiovasc. Diabetol."},{"key":"77068_CR7","doi-asserted-by":"publisher","first-page":"100679","DOI":"10.1016\/j.ajpc.2024.100679","volume":"18","author":"FB Rivera","year":"2024","unstructured":"Rivera, F. B. et al. Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: A meta-analysis of randomized placebo-controlled trials. Am. J. Prev. Cardiol. 18, 100679 (2024).","journal-title":"Am. J. Prev. Cardiol."},{"key":"77068_CR8","doi-asserted-by":"publisher","first-page":"1525623","DOI":"10.3389\/fimmu.2025.1525623","volume":"16","author":"H Sun","year":"2025","unstructured":"Sun, H., Hao, Y., Liu, H. & Gao, F. The immunomodulatory effects of GLP-1 receptor agonists in neurogenerative diseases and ischemic stroke treatment. Front. Immunol. 16, 1525623 (2025).","journal-title":"Front. Immunol."},{"key":"77068_CR9","doi-asserted-by":"publisher","first-page":"204201882312223","DOI":"10.1177\/20420188231222367","volume":"15","author":"SH Alharbi","year":"2024","unstructured":"Alharbi, S. H. Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications. Ther. Adv. Endocrinol. Metab. 15, 20420188231222367 (2024).","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"77068_CR10","doi-asserted-by":"publisher","first-page":"106320","DOI":"10.1016\/j.phrs.2022.106320","volume":"182","author":"G Bendotti","year":"2022","unstructured":"Bendotti, G. et al. The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists. Pharmacol. Res. 182, 106320 (2022).","journal-title":"Pharmacol. Res."},{"key":"77068_CR11","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.rce.2021.04.001","volume":"222","author":"D Patoulias","year":"2022","unstructured":"Patoulias, D. et al. Meta-analysis evaluating the risk of respiratory tract infections and acute respiratory distress syndrome with glucagon-like peptide-1 receptor agonists in cardiovascular outcome trials: Useful implications for the COVID-19 pandemic. Rev. Clin. Esp. (Barc) 222, 229\u2013232 (2022).","journal-title":"Rev. Clin. Esp. (Barc)"},{"key":"77068_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiph.2025.102686","volume":"18","author":"C-S Lee","year":"2025","unstructured":"Lee, C.-S. et al. The impacts of SGLT2 inhibitors on the mortality of patients with tuberculosis. J. Infect. Public Health 18, 102686 (2025).","journal-title":"J. Infect. Public Health"},{"key":"77068_CR13","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.21037\/apm-20-278","volume":"9","author":"HH Chen","year":"2020","unstructured":"Chen, H. H. et al. Effects of dipeptidyl peptidase-4 inhibitor treatment doses on tuberculosis in patients with diabetes: a long-term nationwide population-based cohort study. Ann. Palliat. Med. 9, 2817\u20132825 (2020).","journal-title":"Ann. Palliat. Med."},{"key":"77068_CR14","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1186\/s12890-021-01667-4","volume":"21","author":"E Heo","year":"2021","unstructured":"Heo, E., Kim, E., Jang, E. J. & Lee, C. H. The cumulative dose-dependent effects of metformin on the development of tuberculosis in patients newly diagnosed with type 2 diabetes mellitus. BMC Pulm. Med. 21, 303 (2021).","journal-title":"BMC Pulm. Med."},{"key":"77068_CR15","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/j.chest.2017.11.040","volume":"153","author":"SW Pan","year":"2018","unstructured":"Pan, S. W. et al. The risk of TB in patients with type 2 diabetes initiating metformin vs sulfonylurea treatment. Chest 153, 1347\u20131357 (2018).","journal-title":"Chest"},{"key":"77068_CR16","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/j.1574-695X.1999.tb01397.x","volume":"26","author":"SE Geerlings","year":"1999","unstructured":"Geerlings, S. E. & Hoepelman, A. I. Immune dysfunction in patients with diabetes mellitus (DM). FEMS Immunol. Med. Microbiol. 26, 259\u2013265 (1999).","journal-title":"FEMS Immunol. Med. Microbiol."},{"key":"77068_CR17","first-page":"29","volume":"17","author":"H Sidib\u00e9 el","year":"2007","unstructured":"Sidib\u00e9 el, H. Pulmonary tuberculosis and diabetes: aspects of its epidemiology, pathophysiology, and symptoms. Sante 17, 29\u201332 (2007).","journal-title":"Sante"},{"key":"77068_CR18","first-page":"187","volume":"18","author":"MP Moutschen","year":"1992","unstructured":"Moutschen, M. P., Scheen, A. J. & Lefebvre, P. J. Impaired immune responses in diabetes mellitus: analysis of the factors and mechanisms involved. Relevance to the increased susceptibility of diabetic patients to specific infections. Diabetes Metab. 18, 187\u2013201 (1992).","journal-title":"Diabetes Metab."},{"key":"77068_CR19","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s00281-015-0537-x","volume":"38","author":"D Kiran","year":"2016","unstructured":"Kiran, D., Podell, B. K., Chambers, M. & Basaraba, R. J. Host-directed therapy targeting the Mycobacterium tuberculosis granuloma: a review. Semin. Immunopathol. 38, 167\u2013183 (2016).","journal-title":"Semin. Immunopathol."},{"key":"77068_CR20","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","volume":"9","author":"Z Zheng","year":"2024","unstructured":"Zheng, Z. et al. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal. Transduct. Target Ther. 9, 234 (2024).","journal-title":"Signal. Transduct. Target Ther."},{"key":"77068_CR21","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1517\/14728222.12.7.871","volume":"12","author":"JA Nogueira-Machado","year":"2008","unstructured":"Nogueira-Machado, J. A. & Chaves, M. M. From hyperglycemia to AGE-RAGE interaction on the cell surface: a dangerous metabolic route for diabetic patients. Expert Opin. Ther. Targets 12, 871\u2013882 (2008).","journal-title":"Expert Opin. Ther. Targets"},{"key":"77068_CR22","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1007\/s00125-009-1643-x","volume":"53","author":"I Hadjiyanni","year":"2010","unstructured":"Hadjiyanni, I., Siminovitch, K. A., Danska, J. S. & Drucker, D. J. Glucagon-like peptide-1 receptor signalling selectively regulates murine lymphocyte proliferation and maintenance of peripheral regulatory T cells. Diabetologia 53, 730\u2013740 (2010).","journal-title":"Diabetologia"},{"key":"77068_CR23","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1097\/JS9.0000000000001896","volume":"111","author":"T Liu","year":"2025","unstructured":"Liu, T., Zhou, L., Chen, Y., Lin, J. & Zhu, H. Semaglutide outperforms insulin in restoring neutrophil function against implant-related infection in diabetic and obese mice: experimental research. Int. J. Surg. 111, 273\u2013282 (2025).","journal-title":"Int. J. Surg."},{"key":"77068_CR24","doi-asserted-by":"publisher","first-page":"4358","DOI":"10.1096\/fj.11-190587","volume":"25","author":"HB Bae","year":"2011","unstructured":"Bae, H. B. et al. AMP-activated protein kinase enhances the phagocytic ability of macrophages and neutrophils. FASEB J. 25, 4358\u20134368 (2011).","journal-title":"FASEB J."},{"key":"77068_CR25","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.3389\/fimmu.2020.01582","volume":"11","author":"G Daryabor","year":"2020","unstructured":"Daryabor, G., Atashzar, M. R., Kabelitz, D., Meri, S. & Kalantar, K. The effects of type 2 diabetes mellitus on organ metabolism and the immune system. Front. Immunol. 11, 1582 (2020).","journal-title":"Front. Immunol."},{"key":"77068_CR26","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.2337\/dc18-0287","volume":"41","author":"JA Critchley","year":"2018","unstructured":"Critchley, J. A. et al. Glycemic control and risk of infections among people with type 1 or type 2 diabetes in a large primary care cohort study. Diabetes Care 41, 2127\u20132135 (2018).","journal-title":"Diabetes Care"},{"key":"77068_CR27","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1136\/jech-2018-211231","volume":"73","author":"F Pearson","year":"2019","unstructured":"Pearson, F. et al. Tuberculosis and diabetes: bidirectional association in a UK primary care data set. J. Epidemiol. Community. Health 73, 142\u2013147 (2019).","journal-title":"J. Epidemiol. Community. Health"},{"key":"77068_CR28","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.amepre.2019.12.010","volume":"58","author":"MB Haddad","year":"2020","unstructured":"Haddad, M. B. et al. Tuberculosis infection among people with diabetes: United States population differences by race\/ethnicity. Am. J. Prev. Med. 58, 858\u2013863 (2020).","journal-title":"Am. J. Prev. Med."},{"key":"77068_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-47285-4","volume":"13","author":"D Kibirige","year":"2023","unstructured":"Kibirige, D. et al. Burden and associated phenotypic characteristics of tuberculosis infection in adult Africans with diabetes: a systematic review. Sci. Rep. 13, 19894 (2023).","journal-title":"Sci. Rep."},{"key":"77068_CR30","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1007\/s00125-025-06453-z","volume":"68","author":"CC Kuo","year":"2025","unstructured":"Kuo, C. C. et al. Glucagon-like peptide-1 receptor agonists and gastrointestinal cancer risk in individuals with type 2 diabetes. Diabetologia 68, 1924\u20131936 (2025).","journal-title":"Diabetologia"},{"key":"77068_CR31","doi-asserted-by":"publisher","first-page":"112197","DOI":"10.1016\/j.diabres.2025.112197","volume":"224","author":"TH Liu","year":"2025","unstructured":"Liu, T. H., Lin, Y. M., Yu, T., Wu, J. Y. & Lai, C. C. Risk of dementia after initiation of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: A five-year retrospective cohort analysis of 160,752 patients. Diabetes Res. Clin. Pract. 224, 112197 (2025).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"77068_CR32","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1001\/jama.2015.13480","volume":"314","author":"JS Haukoos","year":"2015","unstructured":"Haukoos, J. S. & Lewis, R. J. The propensity score. JAMA 314, 1637\u20131638 (2015).","journal-title":"JAMA"},{"key":"77068_CR33","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2607","volume":"167","author":"TJ VanderWeele","year":"2017","unstructured":"VanderWeele, T. J. & Ding, P. Sensitivity analysis in observational research: introducing the E-value. Ann. Intern. Med. 167, 268\u2013274 (2017).","journal-title":"Ann. Intern. Med."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77068-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77068-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77068-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T22:37:46Z","timestamp":1790030266000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77068-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,22]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["77068"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-77068-0","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,22]]},"assertion":[{"value":"19 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"10045"}}